Mirja Erika Gunn1, Tuire Lähdesmäki1, Nea Malila1, Mikko Arola1, Marika Grönroos1, Jaakko Matomäki1, Päivi Maria Lähteenmäki1. 1. Department of Pediatrics, Turku University Hospital, PO Box 52, Turku, Finland (M.E.G., T.L., M.G., J.M., P.M.L.); Finnish Cancer Registry, Unioninkatu 22, FI-00130 Helsinki, Finland (N.M.); School of Health Sciences, University of Tampere, Tampere FI-33014, Finland (N.M.); Department of Pediatrics, Tampere University Hospital, PO Box 2000, Tampere FI-33521, Finland (M.A.).
Abstract
BACKGROUND: The population of long-term survivors of childhood brain tumors (BTs) is growing. The aim of our study was to evaluate late-appearing morbidity in BT survivors. METHODS: Patients diagnosed with a BT at the age of 0-15 years between 1970 and 2004, and surviving at least 5 years, were identified from the Finnish Cancer Registry (n = 740). Their late new morbidity ≥ 5 years after cancer diagnosis was assessed using the Hospital Discharge Registry containing hospitalizations and outpatient visits in specialized health care settings. The morbidity of BT survivors was compared with that of the sibling cohort (n = 3615). RESULTS: The 5-year survivors had a significantly increased hazard ratio (HR) for endocrine diseases (HR, 14.7), psychiatric disorders (HR, 1.8), cognitive and developmental disorders (HR, 16.6), neurological diseases (HR, 9.8), disorders of vision and hearing (HR, 10.5), and diseases of the circulatory system (HR, 2.7) compared with the sibling cohort. The HRs for disorders of musculoskeletal system (HR, 1.4) and diseases of the kidney (HR, 2.1) were not significantly increased. Radiation treatment did not explain all of the excess morbidity. Female survivors had a higher risk for disorders of vision and hearing (P = .046). Age at diagnosis did not show an effect on HRs. The HRs for endocrine diseases and disorders of vision or hearing loss were highest for survivors treated in the 1980s or later. CONCLUSIONS: Pediatric BT survivors had significant neurocognitive consequences. This, together with the considerable risk for endocrine morbidity, will motivate us to organize systematic follow-up procedures for pediatric BT survivors.
BACKGROUND: The population of long-term survivors of childhood brain tumors (BTs) is growing. The aim of our study was to evaluate late-appearing morbidity in BT survivors. METHODS:Patients diagnosed with a BT at the age of 0-15 years between 1970 and 2004, and surviving at least 5 years, were identified from the Finnish Cancer Registry (n = 740). Their late new morbidity ≥ 5 years after cancer diagnosis was assessed using the Hospital Discharge Registry containing hospitalizations and outpatient visits in specialized health care settings. The morbidity of BT survivors was compared with that of the sibling cohort (n = 3615). RESULTS: The 5-year survivors had a significantly increased hazard ratio (HR) for endocrine diseases (HR, 14.7), psychiatric disorders (HR, 1.8), cognitive and developmental disorders (HR, 16.6), neurological diseases (HR, 9.8), disorders of vision and hearing (HR, 10.5), and diseases of the circulatory system (HR, 2.7) compared with the sibling cohort. The HRs for disorders of musculoskeletal system (HR, 1.4) and diseases of the kidney (HR, 2.1) were not significantly increased. Radiation treatment did not explain all of the excess morbidity. Female survivors had a higher risk for disorders of vision and hearing (P = .046). Age at diagnosis did not show an effect on HRs. The HRs for endocrine diseases and disorders of vision or hearing loss were highest for survivors treated in the 1980s or later. CONCLUSIONS: Pediatric BT survivors had significant neurocognitive consequences. This, together with the considerable risk for endocrine morbidity, will motivate us to organize systematic follow-up procedures for pediatric BT survivors.
Authors: J Heikens; M C Ubbink; H P van der Pal; P J Bakker; E Fliers; T J Smilde; J J Kastelein; M D Trip Journal: Cancer Date: 2000-05-01 Impact factor: 6.860
Authors: Sari Pietilä; Marja Ala-Houhala; Hanna L Lenko; Aimo P T Harmoinen; Väinö Turjanmaa; Anne Mäkipernaa Journal: Pediatr Blood Cancer Date: 2005-04 Impact factor: 3.167
Authors: Lone Ross; Christoffer Johansen; Susanne Oksbjerg Dalton; Lene Mellemkjaer; Lars H Thomassen; Preben Bo Mortensen; Jørgen H Olsen Journal: N Engl J Med Date: 2003-08-14 Impact factor: 91.245
Authors: James G Gurney; Nina S Kadan-Lottick; Roger J Packer; Joseph P Neglia; Charles A Sklar; Judy A Punyko; Marilyn Stovall; Yutaka Yasui; H Stacy Nicholson; Suzanne Wolden; Dawn E McNeil; Ann C Mertens; Leslie L Robison Journal: Cancer Date: 2003-02-01 Impact factor: 6.921
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Brad J Zebrack; James G Gurney; Kevin Oeffinger; John Whitton; Roger J Packer; Ann Mertens; Norman Turk; Robert Castleberry; ZoAnn Dreyer; Leslie L Robison; Lonnie K Zeltzer Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 50.717
Authors: Carolyn R Bates; Diane Fairclough; Robert B Noll; Maru E Barrera; Mary Jo Kupst; Anna M Egan; Maria A Gartstein; Emily L Ach; Cynthia A Gerhardt; Kathryn Vannatta Journal: Pediatr Blood Cancer Date: 2022-01-19 Impact factor: 3.167
Authors: Elske Sieswerda; Anna Font-Gonzalez; Johannes B Reitsma; Marcel G W Dijkgraaf; Richard C Heinen; Monique W Jaspers; Helena J van der Pal; Flora E van Leeuwen; Huib N Caron; Ronald B Geskus; Leontien C Kremer Journal: PLoS One Date: 2016-07-19 Impact factor: 3.240
Authors: Anna Font-Gonzalez; Elizabeth Lieke A M Feijen; Ronald B Geskus; Marcel G W Dijkgraaf; Helena J H van der Pal; Richard C Heinen; Monique W Jaspers; Flora E van Leeuwen; J B Johannes Reitsma; Hubert N Caron; Elske Sieswerda; Leontien C Kremer Journal: Cancer Med Date: 2017-04-04 Impact factor: 4.452